ABSI Fail-to-Deliver

Absci Corporation (ABSI) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $826.3M, listed on NASDAQ, employing roughly 156 people, carrying a beta of 2.38 to the broader market. Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Led by Sean McClain, public since 2021-07-22.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-04-29
Latest FTD Quantity
921
Latest Price
$4.86
30-Day Avg FTD
87.4K
30-Day Total FTD
2.6M

Showing 30 days of SEC fail-to-deliver data for Absci Corporation.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked ABSI fail to deliver questions

What is the latest ABSI fail-to-deliver count?
As of Apr 29, 2026, Absci Corporation (ABSI) fail-to-deliver quantity is 921 shares, with a 30-day average of 87.4K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do ABSI FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.